Leanne McNabb

Dr. Leanne McNabb


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 July 2017 in Journal of Virology
Verified
Journal Article
Closed access
PDF file
KIKaren Ivinson
Karen Ivinson
GDGeorgia Deliyannis
Georgia Deliyannis
LMLeanne McNabb
Leanne McNabb
LGLara Grollo
Lara Grollo
BGBrad Gilbertson
Brad Gilbertson
LBLorena Brown
Lorena Brown
It is possible to model the progression of influenza virus from the upper respiratory tract to the lower respiratory tract in the mouse using viral inoculum delivered in a restricted manner to the nose. In this model, infection with the A/Udorn/307/72 (Udorn) strain of virus results ultimately in high viral titers in both the trachea and lungs. In contrast, the A/Puerto Rico/8/34 (PR8) strain causes an infection that is almost entirely limited to the nasal passages. The factors that govern the progression of virus down the respiratory tract are not well understood. Here, we show that, while PR8 virus grows to high titers in the nose, an inhibitor present in the saliva blocks further progression of infection to the trachea and lungs and renders an otherwise lethal dose of virus completely asymptomatic.In vitro, the salivary inhibitor was capable of potent neutralization of PR8 virus and an additional 20 strains of type A virus and two type B strains that were tested. The exceptions were Udorn virus and the closely related H3N2 strains A/Port Chalmers/1/73 and A/Victoria/3/75. Characterization of the salivary inhibitor showed it to be independent of sialic acid and other carbohydrates for its function. This and other biochemical properties, together with its virus strain specificity andin vivofunction, indicate that the mouse salivary inhibitor is a previously undescribed innate inhibitory molecule that may have evolved to provide pulmonary protection of the species from fatal influenza virus infection.IMPORTANCEInfluenza A virus occasionally jumps from aquatic birds, its natural host, into mammals to cause outbreaks of varying severity, including pandemics in humans. Despite the laboratory mouse being used as a model to study influenza virus pathogenesis, natural outbreaks of influenza have not been reported in the species. Here, we shed light on one mechanism that might allow mice to be protected from influenza in the wild. We show that virus deposited in the mouse upper respiratory tract will not progress to the lower respiratory tract due to the presence of a potent inhibitor of the virus in saliva. Containing inhibitor-sensitive virus to the upper respiratory tract renders an otherwise lethal infection subclinical. This knowledge sheds light on how natural inhibitors may have evolved to improve survival in this species.

5 February 2014 in Journal of Virological Methods
Verified
Journal Article
Closed access
LMLeanne McNabb
Leanne McNabb
Jennifer BarrJennifer Barr
Jennifer Barr
GCG. Crameri
G. Crameri
SJS. Juzva
S. Juzva
SRS. Riddell
S. Riddell
RLR. Lunt
R. Lunt

21 February 2018 in Journal of Veterinary Diagnostic Investigation
Verified
Journal Article
Closed access
ACAxel Colling
Axel Colling
RLRoss Lunt
Ross Lunt
JBJemma Bergfeld
Jemma Bergfeld
LMLeanne McNabb
Leanne McNabb
KHKim Halpin
Kim Halpin
PDPeter Daniels
Peter Daniels
Obtaining statistically sound numbers of sera from Hendra virus (HeV)-infected horses is problematic because affected individuals usually die or are euthanized before developing a serum antibody response. As a consequence, test validation becomes a challenge. Our approach is an extension of OIE principles for provisional recognition and included 7 validation panels tested across multiple laboratories that provided estimates for test performance characteristics. At a 0.4 S/P cutoff, 16 of 19 sera from HeV-infected horses gave positive results in the HeV soluble G, indirect ELISA (HeVsG iELISA; DSe 84.2% [95% CI: 60.4–96.6%]); 463 of 477 non-infected horse sera tested negative (DSp 97.1% [95% CI: 95.1–98.4%]). The HeVsG iELISA eliminated almost all false-positive results from the previously used HeV iELISA, with marginally decreased relative sensitivity. Assay robustness was evaluated in inter-laboratory and proficiency testing panels. The HeVsG iELISA is considered to be fit for purpose for serosurveillance and international movement of horses when virus neutralization is used for follow-up testing of positive or inconclusive serum samples.

9 September 2019 in Journal of Virological Methods
Verified
Journal Article
Closed access
ARAntonio Di Rubbo
Antonio Di Rubbo
LMLeanne McNabb
Leanne McNabb
RKR. Klein
R. Klein
JWJohn White
John White
ACA. Colling
A. Colling
RLR.A. Lunt
R.A. Lunt

1 June 2015 in Journal of Clinical Microbiology
Verified
Journal Article
Open access
PDF file
ADAlyssa K. Van Dreumel
Alyssa K. Van Dreumel
WMWojtek P. Michalski
Wojtek P. Michalski
LMLeanne McNabb
Leanne McNabb
BSBrian J. Shiell
Brian J. Shiell
NSNagendrakumar B. Singanallur
Nagendrakumar B. Singanallur
GPGrantley R. Peck
Grantley R. Peck
An amino acid consensus sequence for the seven serotypes of foot-and-mouth disease virus (FMDV) nonstructural protein 3B, including all three contiguous repeats, and its use in the development of a pan-serotype diagnostic test for all seven FMDV serotypes are described. The amino acid consensus sequence of the 3B protein was determined from a multiple-sequence alignment of 125 sequences of 3B. The consensus 3B (c3B) protein was expressed as a soluble recombinant fusion protein with maltose-binding protein (MBP) using a bacterial expression system and was affinity purified using amylose resin. The MBP-c3B protein was used as the antigen in the development of a competition enzyme-linked immunosorbent assay (cELISA) for detection of anti-3B antibodies in bovine sera. The comparative diagnostic sensitivity and specificity at 47% inhibition were estimated to be 87.22% and 93.15%, respectively. Reactivity of c3B with bovine sera representing the seven FMDV serotypes demonstrated the pan-serotype diagnostic capability of this bioreagent. The consensus antigen and competition ELISA are described here as candidates for a pan-serotype diagnostic test for FMDV infection.

21 September 2021 in Journal of Virological Methods
Verified
Journal Article
Open access
LMLeanne McNabb
Leanne McNabb
AAAlicia Andiani
Alicia Andiani
ABAistė Bulavaitė
Aistė Bulavaitė
AZAurelija Zvirbliene
Aurelija Zvirbliene
KSKestutis Sasnauskas
Kestutis Sasnauskas
RLRoss Lunt
Ross Lunt
Zoonotic transmission of Hendra virus (HeV) from primary hosts (pteropid bats) to horses, and, occasionally, onward adventitious spread to humans, is associated with high mortality rates in both affected secondary species. The introduction of an effective recombinant G protein vaccine for use in horses has been a major advance for the suppression of disease risk. However, equine HeV vaccination induces neutralising antibody that is indistinguishable from a post infection immune response when using most first line serology assays (eg. VNT and some ELISAs). We have constructed and evaluated an IgM antibody capture (MAC) ELISA which employs yeast expressed HeV nucleoprotein (N). All other serology tests use the G protein which does not detect early infection and is present in the current Hendra virus vaccine and may cause ambiguity in interpretation of results. Thus, this is the first test developed using a N protein which can successfully detect a recent (primarily within the last four weeks) infection of horses with HeV and is not affected by vaccination induced antibody. Testing a limited panel (21 samples) of post infection sera, a normal serum panel (288 samples) and a post vaccination panel (163 samples), we have estimated DSe to be 100% (95% CI, 83.9-100.0%) and DSp to be 98.4% (95% CI, 96.8-99.4%) relative to assigned serology results (VNT, ELISA and Luminex) for the test panels. The HeV IgM MAC ELISA is intended to supplement other molecular and serology test results, with selective use, and is the only serology test which can provide an indication for recent infection which is otherwise not available.